Dr. Hunger's focuses his research on molecular and genomic approaches to identify and clinically evaluate targeted cancer treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) such as Philadelphia chromosome-like (Ph-Like) ALL. The long-term goal of Dr. Hunger’s research is to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.
Improving exclusive human milk feedings for NICU infants is a major public health issue in India, where Diane Spatz, PhD, RN-BC, FAAN, director of The Children’s Hospital of Philadelphia’s Breastfeeding and Lactation Program, spent two weeks teaching nurses and physicians about human milk and implementation of her 10 Step Model for Human Milk and Breastfeeding in Vulnerable Hospitals.
The Teachey Lab studies perturbations in leukemic cell signal transduction pathways with the aim of identifying targeted cancer inhibitors and immunotherapies that can treat children with high-risk leukemias and autoimmune lymphoproliferative syndrome.
